Infliximab and its biosimilars are often used as a treatment for ulcerative colitis (UC), and recent years have seen the collection of real-world data on the use of biosimilar CT-P13 (Inflectra, Remsima) that confirm the product’s equivalent efficacy to that of the reference, Remicade. One newly published study, which assessed patient data from a French nationwide health administrative database, found that not only is biosimilar CT-P13 as effective as the reference product in treating UC, it may also have a lower risk of serious infections.
Infliximab and its biosimilars are often used as a treatment for ulcerative colitis (UC), and recent years have seen the collection of real-world data on the use of biosimilar CT-P13 (Inflectra, Remsima) that confirm the product’s equivalent efficacy to that of the reference, Remicade. One newly published study, which assessed patient data from a French nationwide health administrative database, found that not only is biosimilar CT-P13 as effective as the reference product in treating UC, it may also have a lower risk of serious infections.
The researchers, all employees of a French public organization, assessed the records of 3112 adult patients with UC in this comparative equivalence cohort study. Those who started infliximab between 2015 and 2017 were included in the study, which had a primary outcome of a composite end point of all causes of infliximab failure (including death, surgery, hospitalization, or changing to a different biologic). Follow-up started 30 days after the first infusion and continued until the onset of a predefined outcome or censoring.
In total, 1434 patients (46.1%) received reference infliximab, while 1678 (53.9%) received CT-P13. From January 2015 onward, the proportion of CT-P13 use increased as the biosimilar gained market share in France. University hospitals prescribed the biosimilar more frequently, whereas private hospitals prescribed the reference product more frequently. Patient characteristics were generally similar, although patients who were prescribed CT-P13 tended to have more severe UC.
Overall, 710 patients in the reference product group versus 743 patients in the biosimilar group met the composite end point. In multivariable analysis of the primary outcome, the biosimilar was equivalent to the reference product (hazard ratio [HR], 1.04; 95% CI, 0.94‐1.15). Multivariable analysis of secondary outcomes did not reveal any significant differences between CT‐P13 and its reference for all‐cause hospitalization, UC‐related hospitalization, UC‐related surgery, or reimbursement of another biologic therapy.
A total of 157 serious infections were identified, including 42 gastrointestinal infections. There were fewer serious infections in the CT‐P13 group (42.4 vs 51.9 per 1000 patient-years), including fewer skin and subcutaneous tissue infections (6.6 vs 12.3 per 1000 patient-years), fewer lung infections (7.3 vs 9.5 per 1000 patient-years) and fewer urinary tract infections (4.6 vs 7.3 per 1000 patient-years). Multivariable analysis demonstrated fewer serious infections in the biosimilar group (HR, 0.65; 95% CI, 0.48‐0.88).
Multivariable analysis did not demonstrate a significant difference in terms of malignancies between groups.
“Our observational study of real‐life data suggests that the effectiveness of CT‐P13 is equivalent and the risk of serious infections could be lower than that of the reference product in infliximab‐naive patients with UC,” conclude the authors.
Reference
Meyer A, Redant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis [published online May 22, 2019]. Aliment Pharmacol Ther. doi: 10.1111/apt.15323.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.